Here’s how analysts see Pfizer Inc. (NYSE:PFE) after this past week.

June 19, 2017 - By Vivian Currie

 Here's how analysts see Pfizer Inc. (NYSE:PFE) after this past week.
Investors sentiment decreased to 1.13 in Q4 2016. Its down 0.05, from 1.18 in 2016Q3. It dropped, as 60 investors sold Pfizer Inc. shares while 672 reduced holdings. 115 funds opened positions while 711 raised stakes. 4.12 billion shares or 1.11% more from 4.08 billion shares in 2016Q3 were reported.
Logan Cap, a Pennsylvania-based fund reported 489,577 shares. Tokio Marine Asset Mngmt Limited holds 0.79% or 212,153 shares. Sumitomo Mitsui Asset Mgmt Ltd invested in 0.36% or 570,692 shares. Sumitomo Life Insur accumulated 220,598 shares or 1.02% of the stock. Markston Ltd holds 0.63% in Pfizer Inc. (NYSE:PFE) or 203,389 shares. Rathbone Brothers Public Limited Company owns 1.45% invested in Pfizer Inc. (NYSE:PFE) for 892,088 shares. Pinnacle Advisory Group holds 0.04% or 16,210 shares in its portfolio. Commerzbank Aktiengesellschaft Fi owns 888,216 shares. Btim Corporation holds 88,147 shares or 0.05% of its portfolio. Ballentine Partners owns 0.09% invested in Pfizer Inc. (NYSE:PFE) for 36,949 shares. Lagoda Investment Lp stated it has 1,226 shares or 0.01% of all its holdings. Roosevelt Grp Incorporated owns 177,359 shares. Altavista Wealth Mngmt Inc reported 30,059 shares. Clough Prtnrs Lp reported 294,400 shares stake. Bontempo Ohly Cap Mngmt Limited Liability Com holds 2.66% or 100,346 shares in its portfolio.

Since February 27, 2017, it had 0 insider purchases, and 5 sales for $5.16 million activity. 30,970 shares valued at $1.07M were sold by Dolsten Mikael on Wednesday, March 1. HILL CHARLES H sold $1.23 million worth of Pfizer Inc. (NYSE:PFE) on Thursday, March 9. JOHNSON RADY A had sold 4,500 shares worth $153,855. LANKLER DOUGLAS M sold 20,000 shares worth $693,200.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Among 20 analysts covering Pfizer (NYSE:PFE), 7 have Buy rating, 1 Sell and 12 Hold. Therefore 35% are positive. Pfizer had 45 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Pfizer Inc. (NYSE:PFE) has “Neutral” rating given on Friday, December 2 by Guggenheim. Jefferies maintained Pfizer Inc. (NYSE:PFE) rating on Monday, June 20. Jefferies has “Buy” rating and $40 target. The rating was upgraded by Cowen & Co to “Outperform” on Tuesday, October 20. The stock has “Overweight” rating by Piper Jaffray on Friday, August 28. Morgan Stanley upgraded it to “Overweight” rating and $38 target in Friday, October 2 report. The firm has “Market Perform” rating by Leerink Swann given on Monday, May 2. The firm has “Buy” rating by Jefferies given on Thursday, August 4. The rating was initiated by Berenberg on Thursday, May 12 with “Hold”. Barclays Capital upgraded Pfizer Inc. (NYSE:PFE) on Tuesday, November 29 to “Overweight” rating. As per Friday, August 28, the company rating was maintained by Piper Jaffray. Below is a list of Pfizer Inc. (NYSE:PFE) latest ratings and price target changes.

16/06/2017 Broker: Jefferies Rating: Neutral New Target: $34.00 Target
16/05/2017 Broker: Citigroup Old Rating: Neutral New Rating: Sell Downgrade
28/04/2017 Broker: BMO Capital Markets Rating: Hold New Target: $33.00 Maintain
07/04/2017 Broker: Morgan Stanley Rating: Neutral New Target: $38.00 Maintain
24/03/2017 Broker: Societe Generale Rating: Neutral New Target: $36.00 Maintain

About 2.03 million shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since June 19, 2016 and is downtrending. It has underperformed by 19.46% the S&P500.

Pfizer Inc. is a research-based global biopharmaceutical company. The company has market cap of $198.46 billion. The Firm is engaged in the discovery, development and manufacture of healthcare products. It has a 27.8 P/E ratio. The Company’s global portfolio includes medicines and vaccines, as well as consumer healthcare products.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “Pfizer Vs. Merck: 4 Reasons One Is The Superior Choice” on May 24, 2017, also Twst.com with their article: “Pfizer Inc.: Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational …” published on June 19, 2017, Businesswire.com published: “(tofacitinib citrate) ORAL Strategy Study Published in The Lancet and …” on June 16, 2017. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer Makes Its Presence Known In Lung Cancer” published on June 05, 2017 as well as Seekingalpha.com‘s news article titled: “Pfizer: Buy Shares On Price Weakness” with publication date: June 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.